Cumulative Survival Study (COPERNICUS) have all demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization in patients with heart failure. While none of these trials are large enough to provide definitive results in any particular subgroup, it is of interest for physicians to examine the consistency of results as regards efficacy and safety for various subgroups or risk groups.
Abstract. Context: The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF), the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized
Cumulative Survival Study (COPERNICUS) have all demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization in patients with heart failure. While none of these trials are large enough to provide definitive results in any particular subgroup, it is of interest for physicians to examine the consistency of results as regards efficacy and safety for various subgroups or risk groups.
Objective: To summarize results from both predefined as well as post-hoc subgroup analyses performed in the MERIT-HF trial, and to provide guidance as to whether any subgroup is at increased risk, despite an overall strongly positive effect, and to discuss the difficulties and limitations in conducting such subgroup analyses. For some subgroups we performed metaanalyses with data from the CIBIS II and COPERNICUS trials in order to obtain more robust data on mortality in subgroups with a small number of deaths (e.g. for women).
Setting: MERIT-HF was run in 14 countries, and randomized a total of 3,991 patients with symptomatic systolic heart failure (NYHA class II to IV with ejection fraction ≤0.40). Treatment was initiated with a very low dose with careful titration to a maximum target dose of 200 mg metoprolol succinate controlled release/ extended release (CR/XL), or highest tolerated dose.
Main outcome measures: Total mortality (first primary endpoint), total mortality plus all-cause hospitalization (second primary endpoint), and total mortality plus hospitalization for heart failure (first secondary endpoint) analyzed on a time to first event basis.
Results:
Overall, MERIT-HF demonstrated a 34% reduction in total mortality ( p = 0.00009 nominal) and a 19% reduction for mortality plus all-cause hospitalization ( p = 0.00012). The first secondary endpoint of mortality plus hospitalization for heart failure was reduced by 31% ( p = 0.0000008). The results were remarkably consistent for both primary outcomes and the first secondary outcome across all predefined subgroups as well as nearly all post-hoc subgroups. Metoprolol CR/XL has been very well tolerated, overall as well as in all subgroups analyzed. Overall 87% of the patients reached a dose of 100 mg or more of metoprolol CR/XL once daily, and 64% reached the target dose of 200 mg once daily.
Conclusion: Our results show that when carefully titrated, metoprolol CR/XL can safely be instituted for the overwhelming majority of outpatients with clinically stable systolic heart failure, with minimal side effects or deterioration. The time has come to overcome the barriers that physicians perceive to beta-blocker treatment, and to provide it to the large number of patients with heart failure in need of this therapy, including also high risk patients like elderly patients, patients with severe heart failure, and patients with diabetes. Because of the increased risk, these are the patients in whom treatment will have the greatest impact as shown The MERIT-HF study was supported by grants from AstraZeneca.
Introduction
Three international placebo-controlled survival trials, the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF), and the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) have demonstrated highly significant positive effects on total mortality as well as total mortality plus all-cause hospitalization with beta-blockade in patients with systolic heart failure [1-6]. The results from these trials have been remarkably consistent. Although none of these trials are large enough to provide definitive results in any particular subgroup, it is natural for physicians to examine the consistency of results across various subgroups or risk groups [7] .
As previously described, the International Steering Committee of MERIT-HF stopped the trial on October 31, 1998, on the recommendation from the Independent Safety Committee because of a highly significant reduction of total mortality in the metoprolol CR/XL group. The final results revealed 217 deaths in the placebo group (11.0% per patient year of follow-up) and 145 deaths in the metoprolol CR/XL group (7.2% per patient year of follow-up; 34% reduction, nominal p = 0.00009) [3] . The results of the second primary outcome of total mortality plus all-cause hospitalization were also highly statistically significant (767 vs. 641 events, 19% reduction, p = 0.00012), as were the results of the first secondary outcome of total mortality plus hospitalization for worsening heart failure (439 vs. 311 events, 31% reduction, p = 0.0000008) [4] .
In this paper we examine the consistency of betablocker effect for various predefined risk groups as well as post-hoc subgroups in MERIT-HF. The reason we examine both predefined as well as post-hoc is to provide guidance as to whether any subgroup is at increased risk, despite an overall strongly positive effect, and also to discuss the difficulties and limitations in conducting such subgroup analyses. Analyses of subgroups are both compelling [8] and challenging [9, 10] . Trials are typically designed for adequate power to test the overall treatment effect, and subgroups are rarely large enough to provide definitive answers. Thus, subgroup results will vary around the overall observed treatment effect due to chance and small sample size, so that such analyses should focus on the "overall" consistency rather than the deviation in any particular subgroup.
Methods
In MERIT-HF a total of 3,991 patients with symptomatic chronic heart failure and decreased ejection fraction stabilized on standard treatment were randomized at 313 investigational sites in Belgium, Czech Republic, Denmark, Finland, Germany, Hungary, Iceland, the Netherlands, Norway, Poland, Sweden, Switzerland, UK, and USA [7] . The scientific responsibility rested with an International Steering Committee with representatives from all participating countries [3, 4] . The randomization was performed in 16 randomization regions, three regions in USA (northern, middle and southern states) and one region each for the other participating countries. An optimal allocation procedure (minimization method) was used at randomization taking into account ten characteristics as described previously [3] . This approach assured an excellent balance between the two randomized groups, overall as well as in subgroups. For pre-specified detailed description of Study Objectives, Study Patients, and Study Treatment and Measurements see references [2] [3] [4] 11, 12 ].
An Independent Safety Committee monitored safety issues during the study. The stopping rule for efficacy was based on the total number of expected deaths, analyzed on an intention to treat principle. A Peto-type boundary was used for monitoring a positive trend. The second of three pre-planned interim analyses (50%) showed that the predefined criterion for ending the study had been met and exceeded (Z = 3.807 vs. a boundary value of 2.98) [3, 12] . This interim analysis of total mortality was based on 296 deaths reported by September 15, 1998 giving a point estimate of the hazard ratio of 0.64, indicating a 36% reduction in total mortality (nominal p = 0.00015). The Independent Safety Committee met with the International Executive Committee September 21, 1998, and recommended early closure of the study. The Executive Committee then called for a meeting with the Steering Committee, and the Steering Committee decided to close the study by October 31, 1998. All endpoints were classified by an Independent Endpoint Committee [11] .
Data analysis plan for MERIT-HF
The MERIT-HF study had a predefined Data Analysis Plan, which in detail defined all pre-specified analyses to be performed. The analysis was by intention-to-treat (e.g. all patients randomized). The main analyses utilized the log-rank test for the
